Credit Suisse Group reiterated their outperform rating on shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in a research report released on Monday. The firm currently has a $81.00 target price on the biotechnology company’s stock.

A number of other equities analysts have also issued reports on SRPT. Oppenheimer Holdings, Inc. set a $76.00 target price on shares of Sarepta Therapeutics and gave the stock a buy rating in a research report on Thursday, June 8th. Royal Bank Of Canada reaffirmed a buy rating and set a $60.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, June 22nd. BidaskClub raised shares of Sarepta Therapeutics from a hold rating to a buy rating in a research report on Friday, June 23rd. Morgan Stanley reaffirmed an equal weight rating and set a $31.00 target price on shares of Sarepta Therapeutics in a research report on Friday, June 30th. Finally, Leerink Swann reaffirmed an outperform rating on shares of Sarepta Therapeutics in a research report on Monday, July 3rd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fifteen have issued a buy rating to the company. Sarepta Therapeutics presently has an average rating of Buy and an average target price of $62.79.

Sarepta Therapeutics (NASDAQ SRPT) opened at 49.78 on Monday. Sarepta Therapeutics has a 1-year low of $26.26 and a 1-year high of $63.03. The firm’s 50-day moving average is $42.84 and its 200-day moving average is $36.08. The company’s market capitalization is $3.20 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.92) by $0.46. The company had revenue of $35.01 million for the quarter, compared to the consensus estimate of $22.52 million. During the same period last year, the firm posted ($1.19) EPS. The company’s revenue was up 350000.0% compared to the same quarter last year. Equities research analysts predict that Sarepta Therapeutics will post ($1.22) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.thecerbatgem.com/2017/10/05/credit-suisse-group-reaffirms-outperform-rating-for-sarepta-therapeutics-inc-srpt.html.

In other news, Director Edward M. Md Kaye sold 10,000 shares of the business’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total value of $410,000.00. Following the sale, the director now owns 62,471 shares in the company, valued at approximately $2,561,311. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Alexander Cumbo sold 5,918 shares of the company’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $41.00, for a total transaction of $242,638.00. Following the transaction, the senior vice president now owns 22,793 shares in the company, valued at approximately $934,513. The disclosure for this sale can be found here. Insiders sold a total of 78,056 shares of company stock worth $3,224,208 in the last 90 days. 9.60% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Asymmetry Capital Management L.P. lifted its position in Sarepta Therapeutics by 82.2% during the 2nd quarter. Asymmetry Capital Management L.P. now owns 158,810 shares of the biotechnology company’s stock worth $5,353,000 after buying an additional 71,630 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in Sarepta Therapeutics by 6.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after buying an additional 271 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its position in Sarepta Therapeutics by 85.8% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 20,871 shares of the biotechnology company’s stock worth $704,000 after buying an additional 9,635 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Sarepta Therapeutics by 3.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 40,188 shares of the biotechnology company’s stock worth $1,355,000 after buying an additional 1,435 shares in the last quarter. Finally, Osterweis Capital Management Inc. acquired a new position in Sarepta Therapeutics during the 2nd quarter worth about $3,806,000. Institutional investors and hedge funds own 65.41% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.